Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is a B-cell malignancy. B-cells are a type of white blood cell responsible for producing antibodies. DLBCL is the most common subtype of non-Hodgkin lymphoma among adults, accounting for 25--40% of new cases annually worldwide ([@b1-mmr-20-04-3679]). CD20, a cell-surface protein that is expressed almost exclusively on mature B-cells, is expressed in \>90% of DLBCL cases ([@b2-mmr-20-04-3679]). The conventional chemotherapy regimen for DLBCL has been dominated by cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) since the 1970s. Patients with advanced stage DLBCL have a remission rate of 45--55% and a cure rate of 30--35% with standard CHOP chemotherapy ([@b3-mmr-20-04-3679]). However, it is known that drug resistance is a major obstacle to the success of cancer chemotherapy ([@b4-mmr-20-04-3679]). For DLBCL, 60--70% of patients relapse or develop resistance to CHOP chemotherapy, with a 5-year overall survival rate of 40--50% ([@b5-mmr-20-04-3679]).

Rituximab is a chimeric IgG1 monoclonal antibody targeting CD20. The CD20-binding region of rituximab was derived from a mouse monoclonal antibody through genetic engineering ([@b4-mmr-20-04-3679],[@b6-mmr-20-04-3679]). It has been reported that rituximab is effective for the treatment of refractory or relapsed lymphomas, and that it also has activity in refractory or relapsed DLBCL ([@b7-mmr-20-04-3679],[@b8-mmr-20-04-3679]). Since the late 1990s, adding rituximab to conventional CHOP (R-CHOP) for DLBCL treatment has significantly improved the survival rate across all risk groups ([@b6-mmr-20-04-3679],[@b9-mmr-20-04-3679]). In 2003, R-CHOP was proposed as a first-line standard therapy for DLBCL in the National Comprehensive Cancer Network guideline ([@b10-mmr-20-04-3679],[@b11-mmr-20-04-3679]). DLBCL is curable in the majority of patients treated with R-CHOP ([@b12-mmr-20-04-3679]), nevertheless, the therapeutic mechanism of R-CHOP has not been elucidated.

In the present study, the genes associated with R-CHOP therapy were selected by comparing expression in primary DLBCL with DLBCL after the treatment with R-CHOP. Additionally, a prognosis prediction model for patients with DLBCL treated with R-CHOP was constructed based on prognosis-related genes. The present study comprehensively screened for genes associated with R-CHOP therapy in DLBCL, and evaluated the relationship between gene expression and prognosis.

Materials and methods
=====================

### Data screening and normalization

Expression profiles were retrieved from the National Center of Biotechnology Information Gene Expression Omnibus ([ncbi.nlm.nih.gov/geo/](ncbi.nlm.nih.gov/geo/)) database with 'diffuse large B-cell lymphoma', '*Homo sapiens*' and 'R-CHOP' as the key words. The selection criteria for the dataset were as follows: i) Data are gene expression profiles; ii) data from solid tumors at lymph nodes samples from patients with DLBCL (not blood or cell lines); iii) datasets contained DLBCL samples that did not receive and received R-CHOP treatment; and iv) data also had clinical prognostic information.

In total, two datasets (GSE32918 and GSE57611) ([@b13-mmr-20-04-3679],[@b14-mmr-20-04-3679]) were included in the present study. The GSE32918 dataset \[including 82 germinal center B-cell like (GCB), 53 activated B-cell (ABC) and 37 Type III DLBCL\] was derived from the GPL14951 Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip platform (Illumina, Inc.). In the GSE32918 dataset there are 249 samples from formalin-fixed, paraffin-embedded biopsies (including 53 ABC, 82 GCB and 37 type III), including 62 DLBCL samples from 32 patients not treated with R-CHOP (palliative care or local radiotherapy) and 187 DLBCL samples from 140 patients treated with R-CHOP. Prognostic information was available for 167 patients. This dataset was used as the training dataset. The GSE57611 dataset, derived from the GPL96 \[HG-U133A\] Affymetrix Human Genome U133A Array (Affymetrix; Thermo Fisher Scientific, Inc.), included 148 DLBCL samples (including 79 GCB, 49 ABC and 20 unclassified DLBCLs), among which 30 samples had prognostic information. This dataset was used for validation.

For the GSE32918 dataset that was sequenced on the Illumina platform, the R package limma (version 3.34.0; <http://bioconductor.org/packages/release/bioc/html/limma.html>) ([@b15-mmr-20-04-3679]) was used to transform the skewness distribution of the data to an approximately normal distribution. The data were then normalized using the median normalization method ([@b16-mmr-20-04-3679]). Additionally, for the GSE57611 dataset sequenced using the Affymetrix platform, the R package oligo (version 1.42.0; [bioconductor.org/packages/release/bioc/html/oligo.html](bioconductor.org/packages/release/bioc/html/oligo.html)) ([@b17-mmr-20-04-3679]) was used for format conversion, filling missing data (median method) ([@b18-mmr-20-04-3679]), background correction and data normalization (quantile method) ([@b19-mmr-20-04-3679]).

### Selection of differentially expressed genes (DEGs)

Limma version 3.34.0 ([@b15-mmr-20-04-3679]) in R 3.4.1 was used to calculate the false discovery rate (FDR) and fold change (FC) value of genes between the primary DLBCL sample and R-CHOP treated DLBCL samples in the training dataset. The genes with an FDR\<0.05 and \|logFC\|\>0.5 were considered as DEGs. On the basis of the expression level of the DEGs, Euclidean distance ([@b20-mmr-20-04-3679]) based bilateral hierarchical clustering ([@b21-mmr-20-04-3679]) was performed using pheatmap (version 1.0.8; <http://cran.r-r-project.org/package=pheatmap>) ([@b22-mmr-20-04-3679]) in R 3.4.1 and the results were visualized using a heatmap.

Construction and validation of the prognostic risk prediction model
-------------------------------------------------------------------

### Selection of the optimum combination of prognostic genes

The DEGs significantly associated with prognosis in the training set were further selected using the univariate Cox regression analysis in Survival (version 2.4; [cran.r-project.org/web/packages/survival/index.html](cran.r-project.org/web/packages/survival/index.html)) ([@b23-mmr-20-04-3679]) in R 3.4.1. A log-rank P\<0.05 was used as the threshold. The prognosis-associated DEGs were used for Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses using the Database for Annotation, Visualization and Integrated Discovery (version 6.8; [david.ncifcrf.gov/](david.ncifcrf.gov/)) ([@b24-mmr-20-04-3679]). Subsequently, the optimum combination of prognostic genes were selected according to the hazard parameter 'λ' that was calculated 1,000 times using a cross-validation likelihood algorithm based on the Cox proportional hazards (Cox-PH) model ([@b25-mmr-20-04-3679]) of L1-penalized regularization regression algorithm in the Penalized package version 0.9--51 ([@b26-mmr-20-04-3679]) in R 3.4.1.

### Establishment and verification of the risk prediction model

Based on the aforementioned DEGs combination and Cox-PH regression coefficients, a risk score system for each sample was established using gene expression values weighted by regression coefficients. The risk score of each sample was calculated as follows: Risk score = β~gene\ 1~ × expression~gene\ 1~ + β~gene\ 2~ × expression~gene\ 2~+... +β~gene\ n~ × expression~gene\ n~, where β indicates the Cox-PH regression coefficient.

The samples in the training set were divided into high risk score and low risk score groups according to the median risk score. The correlation between the risk prediction model and prognosis was evaluated using Kaplan-Meier survival curves in Survival version 2.41-1 in R 3.4.1. The correlation was verified in the validation dataset (GSE57611).

### Function analysis of DEGs between high and low risk score groups

The DEGs between high and low risk score groups were selected using limma version 3.34.0 ([@b15-mmr-20-04-3679]) with thresholds of FDR\<0.05 and \|log~2~FC\|\>0. DEGs were considered to be significantly correlated with risk grouping, and were then subjected to GO and KEGG enrichment analyses, if the threshold of P\<0.05. The analysis process is shown in [Fig. 1](#f1-mmr-20-04-3679){ref-type="fig"}.

Results
=======

### Data preprocessing and DEG screening

After normalization, the DEGs between R-CHOP-treated and primary DLBCL samples were screened. In total, 801 DEGs were identified, including 386 that were upregulated and 415 that were downregulated ([Fig. 2A](#f2-mmr-20-04-3679){ref-type="fig"}). The Log~2~ Kernel density curve based on the expression of the DEGs is shown in [Fig. 2B](#f2-mmr-20-04-3679){ref-type="fig"}. As shown in [Fig. 2B](#f2-mmr-20-04-3679){ref-type="fig"}, 51.81% (415/801) of DEGs were significantly downregulated and 48.19% (386/801) of DEGs were significantly upregulated in R-CHOP treated DLBCL samples. The bidirectional hierarchical clustering heatmap based on the expression levels of the DEGs is shown in [Fig. 2C](#f2-mmr-20-04-3679){ref-type="fig"}. The DEGs in the different samples separated clearly, as represented by the distinct colors in the heatmap.

Construction and validation of the prognostic risk prediction model
-------------------------------------------------------------------

### Selection of the optimal combination of prognostic genes

Based on the identified DEGs and the prognostic information in GSE32918, a total of 116 genes that were significantly correlated with prognosis were selected using univariate Cox regression analysis. Functional analysis of the 116 genes identified 18 significant GO terms, including 11 biological processes (BP), four molecular functions (MF) and three cellular components (CC), and eight KEGG pathways ([Table I](#tI-mmr-20-04-3679){ref-type="table"}). The results of this analysis showed that the DEGs identified were significantly associated with the cell cycle and transcription regulation associated biological processes, as well as significantly involved in 'hsa04060:cytokine-cytokine receptor interaction' and 'hsa04014:Ras signaling pathway'.

The optimal combination of prognostic genes was determined using the Cox-PH model. When the parameter 'λ' was 10.289, the cross-validation likelihood reached the maximum value of −475.733 ([Fig. 3A](#f3-mmr-20-04-3679){ref-type="fig"}). Under this parameter, the Cox-PH model identified a 12 gene combination ([Fig. 3B](#f3-mmr-20-04-3679){ref-type="fig"}). The 12 genes are listed in [Table II](#tII-mmr-20-04-3679){ref-type="table"}.

### Establishment and evaluation of the risk prediction model

According to the 12-gene combination, as well as the Cox-PH regression coefficients, the sample risk score prediction model was constructed as follows: Risk score = (−0.605) × expression~ANKS1B~ + (−0.179) × expression~CAMK1~ + (−0.496) × expression~CES1~ + (−1.468) × expression~CTLA4~ + (0.948) × expression~CXCL2~ + (0.379) × expression~DNAJC12~ × (−0.619) × expression~EFNA5~ + (0.317) × expression~FEZ1~ + (−0.114) × expression~HOPX~ + (−0.039) × expression~HPCAL4~ + (0.187) × expression~IL17RB~ + (−0.348) × expression~MUC16~.

Based on this model, the risk score of each sample in GSE32918 (the training set) was calculated and the samples were divided into high risk score and low risk score groups according to the median risk score. Kaplan-Meier survival curves were used to evaluate overall survival prognosis in the 167 DLBCL samples in the training set. As shown in [Fig. 4A](#f4-mmr-20-04-3679){ref-type="fig"}, the patients with a high risk score had significantly shorter survival times (P=1.84х10^−8^). The prediction model had a high sensitivity, with the area under the receiver operating characteristic curve (AUC) of 0.942. Additionally, the prediction performance of the model was confirmed using the validation set. Patients with high risk scores had shorter survival times (P=3.96х10^−2^; AUC=0.889; [Fig. 4B](#f4-mmr-20-04-3679){ref-type="fig"}).

In order to analyze the performance of the prediction model in DLBCL and R-CHOP-treated DLBCL samples, the samples in the training set were divided into DLBCL and R-CHOP-treated DLBCL groups, and the risk score model was analyzed in the two sets of samples. As shown in [Fig. 5](#f5-mmr-20-04-3679){ref-type="fig"}, the predictive ability of the risk prediction model in the R-CHOP-treated DLBCL group (P=4.38х10^−5^) was superior to that in the untreated DLBCL group (P=0.453). This indicated that the risk score model had a high prediction power in R-CHOP-treated DLBCLs.

### Function annotation of risk associated genes

A total of 729 DEGs were identified comparing the high and low risk score samples in the training set, among which 314 DEGs were significantly downregulated and 415 were significantly upregulated in the high risk score group ([Fig. 6A](#f6-mmr-20-04-3679){ref-type="fig"}). The volcano plot is shown in [Fig. 6A](#f6-mmr-20-04-3679){ref-type="fig"} and the heatmap based on the expression level changes of the DEGs, with the risk score, is shown in [Fig. 6B](#f6-mmr-20-04-3679){ref-type="fig"}. These DEGs were used for functional annotation; 30 significant GO terms (16 BP, nine CC and five MF) and nine KEGG pathways were identified ([Table III](#tIII-mmr-20-04-3679){ref-type="table"} and [Fig. 7](#f7-mmr-20-04-3679){ref-type="fig"}). The DEGs were significantly enriched in functions associated with 'response to DNA damage stimulus', 'cell cycle' and the 'cytokine-cytokine receptor interaction' pathways.

Discussion
==========

In the present study, 801 DEGs were identified between R-CHOP-treated DLBCL and primary DLBCL samples. From the 801 DEGs, 116 prognosis-associated genes were identified; these genes were significantly enriched in 18 GO terms and eight pathways. Using the Cox-PH model, an optimal combination of 12 genes was selected, and the sample risk score prediction model was constructed and validated. The samples in the training set were divided into high and low risk score groups based on the risk score. The DEGs between high and low risk score groups were significantly enriched in functions associated with 'response to DNA damage stimulus', 'cell cycle' and the 'cytokine-cytokine receptor interaction' pathway.

It has been reported that the signal transduction system, comprising growth factors, cytoplasmic secondary messengers and transmembrane receptor proteins, optimizes the growth and metastasis of tumor cells in malignancies, and is therefore considered as a target for cancer therapy ([@b27-mmr-20-04-3679]). Functional enrichment analysis showed that calcium/calmodulin dependent protein kinase I (*CAMK1*), a component of the calmodulin-dependent protein kinase cascade, and hippocalcin like 4 (*HPCAL4*) were enriched in functions associated with 'signal transduction' (GO:0007165). The roles of *CAMK1* and *HPCAL4* in cancer have not been fully analyzed to the best of our knowledge, but it is speculated that *CAMK1* and *HPCAL4* may be targets of R-CHOP in DLBCL given their association with signal transduction.

Among the 12 genes, five were found to be associated with 'protein binding' (GO:0005515), including *CAMK1*, cytotoxic T-lymphocyte associated protein 4 (*CTLA4*), fasciculation and elongation protein ζ1 (*FEZ1*), HOP homeobox (*HOPX*), and mucin 16, cell surface associated (*MUC16*). CTLA4 is a coinhibitory receptor that regulates T-cell activation during the initiation and maintenance of adaptive immune responses. The blocking of CTLA4 promotes antitumor T-cell immunity ([@b28-mmr-20-04-3679]). In addition, rituximab could enhance the production of CTLA4 by regulatory T-cells ([@b29-mmr-20-04-3679]) and B-cells ([@b30-mmr-20-04-3679]). FEZ1 encodes a 67 kDa leucine-zipper protein with a region similar to cAMP-dependent activated protein ([@b31-mmr-20-04-3679]), which has been found to be mutated in solid tumors ([@b32-mmr-20-04-3679]). In *FEZ1* null cancer cells, *FEZ1* introduction has been reported to reduce cell growth, while *FEZ1* inhibition stimulates cell growth, suggesting a role for FEZ1 in human cancer ([@b33-mmr-20-04-3679]). *HOPX* belongs to the homeobox gene family and is ubiquitously expressed in normal tissues ([@b34-mmr-20-04-3679]). It has been reported that enforced *HOPX* expression inhibits tumor progression and that *HOPX* knockdown restores tumor aggressiveness ([@b35-mmr-20-04-3679]). MUC16 is a member of the mucin family that is reported to be involved in tumorigenicity and therapeutic resistance in pancreatic cancer ([@b36-mmr-20-04-3679]). Moreover, *MUC16* is overexpressed in multiple types of cancer and has an important role in acquired resistance to therapy ([@b37-mmr-20-04-3679]). However, to the best of our knowledge, there is no previous evidence showing the association of these DEGs with CD20 or DLBCL. Given the roles of the five genes in cancer, it is speculated that R-CHOP may target *CAMK1, CTLA4, FEZ1, HOPX* and *MUC16*. The negative effect of *CTLA4* on risk scores in DLBCL samples showed that the increased expression of *CTLA4* contributed to the efficiency of rituximab therapy. Similar hypotheses could be made for the *CAMK1, MUC16* and *HOPX* genes.

The other two DEGs, C-X-C motif chemokine ligand 2 (*CXCL2*) and ephrin A5 (*EFNA5*) were found to be involved in several signaling pathways, including the 'Ras signaling pathway', 'chemokine signaling pathway' and 'PI3K-Akt signaling pathway'. These signaling mechanisms are fundamental pathways in normal and tumor cells, even if tumor cells may be more reliant on these pathways ([@b38-mmr-20-04-3679]). The Ras signaling pathway is commonly activated in tumors ([@b38-mmr-20-04-3679]). Rational therapies targeting the Ras signaling pathways inhibit tumor survival, growth and spread ([@b39-mmr-20-04-3679]). The PI3K-Akt signaling pathway regulates multiple tumorigenesis-associated cellular processes, including cell proliferation, growth and motility ([@b40-mmr-20-04-3679]). Mutations or altered expression levels of components of the PI3K-Akt pathway are implicated in human cancer ([@b41-mmr-20-04-3679]). Therefore, several drugs, alone and in combination, including rituximab, targeting the PI3K-Akt signaling pathway are in clinical trials, in both hematologic malignancies and solid tumors ([@b42-mmr-20-04-3679],[@b43-mmr-20-04-3679]). It has been previously reported that rituximab-induced apoptosis in the B-cell lymphoma cell line SD07 is mediated by PI3K-Akt dephosphorylation or suppression ([@b43-mmr-20-04-3679]). The normal development of cells depends on chemokines and their receptors, and tumor progression also requires stimulation by chemokines ([@b44-mmr-20-04-3679]). CXCL2, which is part of the CXC chemokine family, promotes inflammation and supports tumor growth ([@b45-mmr-20-04-3679]). Taken together, it is speculated that *CXCL2* and *EFNA5* may be targeted by R-CHOP via these signaling pathways. However, to the best of our knowledge, there is no evidence showing the association of CXCL2 alteration with DLBCL, R-CHOP therapy or rituximab.

Interleukin 17 receptor B (*IL17RB*) was enriched in the 'cytokine-cytokine receptor interaction' pathway (hsa04060). IL17RB, a proinflammatory cytokine, is the receptor of IL17B ([@b46-mmr-20-04-3679]). Cytokines play important roles in the localization of normal or malignant B-cells in tissues ([@b47-mmr-20-04-3679]). IL17RB is expressed in endocrine tissues and is expressed in normal mammary epithelial cells at negligible levels ([@b48-mmr-20-04-3679]). However, IL17RB was previously found to be highly expressed in malignant mammary epithelial cells ([@b49-mmr-20-04-3679]). The overexpression of IL17B has been reported to be associated with poor prognosis in breast cancer ([@b50-mmr-20-04-3679]). Previous studies have reported that certain cytokines, including interleukin-4 and tumor necrosis factor-α (TNF-α) upregulate the expression of the CD20 antigen, increasing the efficacy of rituximab ([@b51-mmr-20-04-3679],[@b52-mmr-20-04-3679]). IL-17 and TNF-α are inflammatory cytokines that are co-expressed by T helper 17 cells in a number of tumors ([@b53-mmr-20-04-3679]). The findings indicate that IL17RB has a role in R-CHOP-mediated therapy for DLBCL.

In addition to the aforementioned genes, the remaining three DEGs were not enriched in GO terms or pathways. Ankyrin repeat and sterile α motif domain-containing protein 1B (*ANKS1B*) is involved in tyrosine kinase signal transduction ([@b54-mmr-20-04-3679]), and is primarily expressed in the brain and testis ([@b55-mmr-20-04-3679]). *ANKS1B* is involved in apoptosis, and thus, has potential functions in cancer development ([@b56-mmr-20-04-3679]). A previous study demonstrated that the expression of *ANKS1B* gene is associated with the development of smoking-related clear cell renal cell carcinoma ([@b57-mmr-20-04-3679]). Carboxylesterase 1 (*CES1*) is a member of the carboxylesterase family and is important in phase I metabolism ([@b58-mmr-20-04-3679]). Carboxylesterases mediate the metabolism of drug compounds with thioester, ester and amide linkages, and the detoxification of xenobiotics ([@b59-mmr-20-04-3679]). Carboxylesterases are found to hydrolyze two anticancer agents, capecitabine and irinotecan ([@b60-mmr-20-04-3679]). DnaJ heat shock protein family member C12 (*DNAJC12*) encodes a member of a subclass of the heat shock protein 40 kDa family that is involved in a number of important biological functions ([@b61-mmr-20-04-3679],[@b62-mmr-20-04-3679]). High expression of DNAJC12 functions as a negative predictive factor for the response to neoadjuvant concurrent chemotherapy in rectal cancer ([@b63-mmr-20-04-3679]). Little information is available regarding these genes, and their role in DLBCL and other diseases. The combination of these genes in the risk predication model suggests their important roles in DLBCL therapy. It is speculated that *ANKS1B, CES1* and *DNAJC12* may serve as important target genes in R-CHOP therapy in DLBCL.

In conclusion, the optimal combination of 12 genes to predict prognosis risk, including *CAMK1, HPCAL4, CXCL2* and *EFNA5*, was selected based on the differential expression of these genes between R-CHOP-treated DLBCL and primary DLBCL groups. These genes were utilized in the construction of the prognosis prediction model in DLBCL after R-CHOP treatment. These genes may also serve as target genes of R-CHOP in DLBCL. To the best of our knowledge, most of these DEGs have not been reported to be associated with DLBCL and CD20 or rituximab-mediated therapy, highlighting the novel insights the present study provides into the pathogenesis and treatment of DLBCL.
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![Analysis process. The GSE32918 dataset was used for the identification of DEGs. R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy; DLBCL, diffuse large B-cell lymphoma; DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes; Cox-PH, Cox proportional hazards model.](MMR-20-04-3679-g00){#f1-mmr-20-04-3679}

![Results of screening for DEG. (A) Volcano plot. Orange and blue dots indicate significantly upregulated and downregulated DEGs, respectively. The red dotted horizontal line indicates an FDR\<0.05 and the two red dotted vertical lines indicate \|logFC\|\>0.5. (B) Log~2~ Kernel density curve based on DEGs. (C) Bidirectional hierarchical clustering heatmap based on the expression level of the DEGs. The heatmap colors indicate the expression level; blue indicates low expression while red indicates high expression. DEGs, differentially expressed genes; FDR, false discovery rate; FC, fold change; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy.](MMR-20-04-3679-g01){#f2-mmr-20-04-3679}

![Selection of optimal prognostic genes. (A) Curve of cvl screening for the λ parameter. The optimized parameter λ, indicator of the hazard, was obtained by 1,000 rounds of cross-validated likelihood (cvl) circular calculation. The horizontal and vertical axes represent different values of λ and cvl, respectively. The crossing of the red dotted line represents λ of 10.289 when cvl takes the maximum (−475.733). (B) Coefficient distribution diagram of the optimal combination of prognostic genes based on the Cox proportional hazards model. cvl, cross-validation likelihood; ANKS1B, ankyrin repeat and sterile α motif domain-containing protein 1B; CAMK1, calcium/calmodulin dependent protein kinase I; CES, carboxylesterase 1; CTLA4, cytotoxic T-lymphocyte associated protein 4; CXCL2, C-X-C motif chemokine ligand 2; DNAJC12, DnaJ heat shock protein family member C12; EFNA5, ephrin A5; FEZ1, fasciculation and elongation protein ζ1; HOPX, HOP homeobox; HPCAL4, hippocalcin like 4; IL17RB, interleukin 17 receptor B; MUC16, mucin 16, cell surface associated.](MMR-20-04-3679-g02){#f3-mmr-20-04-3679}

![Prediction model and overall survival Kaplan-Meier curves. Kaplan-Meier overall survival curves (left) and receiver operating characteristic curves (right) based on the optimal gene combination in (A) training set (GSE32918) and (B) validation set (GSE57611). Blue and red curves represent the low and high risk score groups, respectively. AUC, area under curve.](MMR-20-04-3679-g03){#f4-mmr-20-04-3679}

![Prediction model and the overall survival Kaplan-Meier curves. Overall survival Kaplan-Meier curves based on the optimal gene combination in (A) DLBCL and (B) R-CHOP treated DLBCL samples. Blue and red curves represent the low risk score and high risk score groups, respectively. DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy.](MMR-20-04-3679-g04){#f5-mmr-20-04-3679}

![DEGs between high and low risk groups. (A) Volcano plot. Orange and blue dots indicate significantly upregulated and downregulated DEGs, respectively. The red dotted horizontal line indicates an FDR\<0.05 and the two red dotted vertical lines indicate \|logFC\|\>0.5. (B) Heatmap based on the expression level of DEGs. DEGs, differentially expressed genes; FDR, false discovery rate; FC, fold change.](MMR-20-04-3679-g05){#f6-mmr-20-04-3679}

![Gene enrichment analysis. (A) Bar graph of the GO terms significantly associated with the differentially expressed genes. The horizontal axis represents the number of genes and the vertical axis shows the term. The color of the bars indicates the significance level. (B) Pie chart of KEGG pathways identified. Each segment represents a different KEGG pathway. The colors represent significant P-values (P\<0.05) for each section; red low P-value, blue high P-value. KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; GO, Gene Ontology; CC, cellular component; BP, biological process.](MMR-20-04-3679-g06){#f7-mmr-20-04-3679}

###### 

GO and KEGG pathway enrichment results for the differentially expressed genes that were significantly correlated with prognosis.

  A, Biological process                                                                  
  -------------------------------------------------------------------------- ----------- -------------
  GO:0007411\~axon guidance                                                  6           0.003641
  GO:0007229\~integrin-mediated signaling pathway                            5           0.003814
  GO:0045892\~negative regulation of transcription, DNA-templated            10          0.004883
  GO:0045893\~positive regulation of transcription, DNA-templated            10          0.005975
  GO:0016055\~Wnt signaling pathway                                          6           0.007186
  GO:0007165\~signal transduction                                            16          0.00733
  GO:0051726\~regulation of cell cycle                                       5           0.008414
  GO:0030036\~actin cytoskeleton organization                                5           0.009895
  GO:0043547\~positive regulation of GTPase activity                         9           0.029303
  GO:0006355\~regulation of transcription, DNA-templated                     17          0.030824
  GO:0042127\~regulation of cell proliferation                               5           0.031547
                                                                                         
  **B, Cellular component**                                                              
                                                                                         
  **Term**                                                                   **Count**   **P-value**
                                                                                         
  GO:0016020\~membrane                                                       25          0.003065
  GO:0005667\~transcription factor complex                                   6           0.00656
  GO:0005886\~plasma membrane                                                36          0.018833
                                                                                         
  **C, Molecular function**                                                              
                                                                                         
  **Term**                                                                   **Count**   **P-value**
                                                                                         
  GO:0005125\~cytokine activity                                              5           0.025713
  GO:0005515\~protein binding                                                67          0.027873
  GO:0003700\~transcription factor activity, sequence-specific DNA binding   12          0.041048
  GO:0044212\~transcription regulatory region DNA binding                    5           0.04659
                                                                                         
  **D, KEGG pathway**                                                                    
                                                                                         
  **Term**                                                                   **Count**   **P-value**
                                                                                         
  hsa04060:Cytokine-cytokine receptor interaction                            7           0.00103
  hsa04014:Ras signaling pathway                                             6           0.00354
  hsa04015:Rap1 signaling pathway                                            5           0.008964
  hsa05200:Pathways in cancer                                                7           0.009679
  hsa04062:Chemokine signaling pathway                                       4           0.019075
  hsa04151:PI3K-Akt signaling pathway                                        5           0.030569
  hsa04310:Wnt signaling pathway                                             3           0.030827
  hsa04514:Cell adhesion molecules (CAMs)                                    3           0.032028

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Optimal genes list based on Cox proportional hazards model of L1-penalized regularization regression algorithm.

  Gene      Coef     Hazard ratio           P-value
  --------- -------- ---------------------- --------------
  ANKS1B    −0.605   0.767 (0.658--0.895)   6.568×10^−4^
  CAMK1     −0.179   0.837 (0.729--0.959)   1.045×10^−2^
  CES1      −0.496   0.846 (0.751--0.953)   5.423×10^−3^
  CTLA4     −1.468   0.716 (0.627--0.817)   5.008×10^−7^
  CXCL2     0.948    1.559 (1.219--1.994)   5.637×10^−4^
  DNAJC12   0.379    1.480 (1.239--1.767)   1.332×10^−5^
  EFNA5     −0.619   0.811 (0.719--0.915)   5.862×10^−4^
  FEZ1      0.317    1.214 (1.059--1.390)   5.066×10^−3^
  HOPX      −0.114   0.859 (0.750--0.984)   2.703×10^−2^
  HPCAL4    −0.039   0.666 (0.531--0.837)   4.057×10^−4^
  IL17RB    0.187    1.137 (1.023--1.263)   1.627×10^−2^
  MUC16     −0.348   0.837 (0.731--0.957)   8.829×10^−3^

Coef, coefficient; ANKS1B, ankyrin repeat and sterile α motif domain-containing protein 1B; CAMK1, calcium/calmodulin dependent protein kinase I; CES, carboxylesterase 1; CTLA4, cytotoxic T-lymphocyte associated protein 4; CXCL2, C-X-C motif chemokine ligand 2; DNAJC12, DnaJ heat shock protein family member C12; EFNA5, ephrin A5; FEZ1, fasciculation and elongation protein ζ1; HOPX, HOP homeobox; HPCAL4, hippocalcin like 4; IL17RB, interleukin 17 receptor B; MUC16, mucin 16, cell surface associated.

###### 

GO and KEGG pathway enrichment results for DEGs.

  A, Biological process                                           
  --------------------------------------------------- ----------- --------------
  GO:0006974\~response to DNA damage stimulus         32          2.47×10^−04^
  GO:0006281\~DNA repair                              26          4.14×10^−04^
  GO:0045184\~establishment of protein localization   50          0.002456
  GO:0006259\~DNA metabolic process                   36          0.002753
  GO:0015031\~protein transport                       49          0.003342
  GO:0008104\~protein localization                    55          0.003533
  GO:0022402\~cell cycle process                      38          0.00521
  GO:0033554\~cellular response to stress             38          0.005394
  GO:0007049\~cell cycle                              48          0.007516
  GO:0051301\~cell division                           22          0.013451
  GO:0022403\~cell cycle phase                        28          0.016532
  GO:0000278\~mitotic cell cycle                      25          0.024163
  GO:0032989\~cellular component morphogenesis        26          0.029787
  GO:0042127\~regulation of cell proliferation        45          0.032887
  GO:0000279\~M phase                                 22          0.038695
  GO:0042981\~regulation of apoptosis                 45          0.045193
                                                                  
  **B, Cellular component**                                       
  **Term**                                            **Count**   **P-value**
                                                                  
  GO:0031974\~membrane-enclosed lumen                 101         5.31×10^−04^
  GO:0043233\~organelle lumen                         99          6.35×10^−04^
  GO:0070013\~intracellular organelle lumen           97          6.75×10^−04^
  GO:0031981\~nuclear lumen                           76          0.008073
  GO:0019898\~extrinsic to membrane                   31          0.012421
  GO:0000793\~condensed chromosome                    12          0.012999
  GO:0009897\~external side of plasma membrane        14          0.017106
  GO:0005578\~proteinaceous extracellular matrix      21          0.028573
  GO:0043235\~receptor complex                        10          0.039703
                                                                  
  **C, Molecular function**                                       
                                                                  
  **Term**                                            **Count**   **P-value**
                                                                  
  GO:0019955\~cytokine binding                        11          0.014221
  GO:0019900\~kinase binding                          15          0.015941
  GO:0005524\~ATP binding                             75          0.041085
  GO:0019899\~enzyme binding                          31          0.042744
  GO:0030554\~adenyl nucleotide binding               79          0.046193
                                                                  
  **D, KEGG pathway**                                             
                                                                  
  **Term**                                            **Count**   **P-value**
                                                                  
  hsa04060:Cytokine-cytokine receptor interaction     20          0.002507
  hsa04115:p53 signaling pathway                      7           0.008288
  hsa00590:Arachidonic acid metabolism                5           0.024164
  hsa00010:Glycolysis/Gluconeogenesis                 5           0.028166
  hsa04062:Chemokine signaling pathway                11          0.032858
  hsa04660:T cell receptor signaling pathway          7           0.035535
  hsa04514:Cell adhesion molecules (CAMs)             8           0.038001
  hsa04110:Cell cycle                                 7           0.04925

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed gene.

[^1]: Contributed equally
